This proposal outlines a comprehensive plan for the PI to develop an academic career in Biochemical Genetics. The candidate, an Instructor in Pediatrics at The Children's Hospital of Philadelphia (CHOP), receives basic science research mentoring from Craig Thompson, MD at the University of Pennsylvania, and clinical mentoring from Marc Yudkoff, MD of CHOP'S Division of Child Development, Rehabilitation Medicine and Metabolic Disease. Pediatric mitochondrial diseases are untreatable genetic disorders that disrupt metabolism of lipids and other substances. They impair many tissues, including the bone marrow, where failure of cell proliferation results in increased susceptibility to infection. Because cells in the bone marrow depend on growth factor stimulation to direct their metabolism, we hypothesize that mitochondrial diseases prevent growth factors from eliciting metabolic responses needed to support the cell proliferation characteristic of immune responses. We propose to study how growth factors stimulate synthesis of fatty acids and lipids, because they must be produced in abundance in order for cells to proliferate. Our long-term goal is to understand why genetic defects in mitochondrial metabolism impair lipid synthesis in growth factor - dependent cells, and to use this information to improve the health of children with such diseases. In our first aim, we study how growth factor stimulation of the kinase Akt directs fatty acid synthesis. In our second aim, we study the mechanism and importance of growth factor suppression of fatty acid degradation. In our third aim, we focus on defects in the mitochondrial electron transport chain (ETC) that impair lipid synthesis. We will establish models of ETC dysfunction and use them to test the hypothesis that activation of the kinase AMPK orchestrates abnormalities in lipid metabolism seen in ETC diseases. Mitochondrial diseases continue to be a significant source of mental retardation, morbidity and mortality in children. Diagnosis and treatment of these disorders continues to be inadequate, in part because of an incomplete understanding of their pathophysiology. The studies proposed here will provide a foundation to understand connections between growth factor signaling, lipid biology and mitochondrial metabolism, and could suggest new therapeutic avenues to improve growth and immune function in these children.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08DK072565-06
Application #
7842510
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Hyde, James F
Project Start
2006-07-01
Project End
2011-06-30
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
6
Fiscal Year
2010
Total Cost
$133,920
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Pediatrics
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Mullen, Andrew R; Wheaton, William W; Jin, Eunsook S et al. (2012) Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481:385-8
Marin-Valencia, Isaac; Cho, Steve K; Rakheja, Dinesh et al. (2012) Glucose metabolism via the pentose phosphate pathway, glycolysis and Krebs cycle in an orthotopic mouse model of human brain tumors. NMR Biomed 25:1177-86
Marin-Valencia, Isaac; Yang, Chendong; Mashimo, Tomoyuki et al. (2012) Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab 15:827-37
Cheng, Tzuling; Sudderth, Jessica; Yang, Chendong et al. (2011) Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci U S A 108:8674-9
Frezza, Christian; Zheng, Liang; Folger, Ori et al. (2011) Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 477:225-8
DeBerardinis, Ralph J (2011) Serine metabolism: some tumors take the road less traveled. Cell Metab 14:285-6
Yamasaki, Toshinari; Tran, Tram Anh T; Oz, Orhan K et al. (2011) Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC. Nat Rev Urol 8:165-71
Rajagopalan, Kartik N; DeBerardinis, Ralph J (2011) Role of glutamine in cancer: therapeutic and imaging implications. J Nucl Med 52:1005-8
DeBerardinis, R J; Cheng, T (2010) Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29:313-24
DeBerardinis, Ralph J (2010) 2010 Keystone Symposium: Metabolism and Cancer Progression. Future Oncol 6:893-5

Showing the most recent 10 out of 17 publications